3-溴-6-异丙氧基甲基吡啶 | 1239611-34-7

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 3-溴-6-异丙氧基甲基吡啶
• 英文名称: 3-bromo-6-isopropoxy-2-methyl -pyridine
• 英文别名: 3-Bromo-6-isopropoxy-2-methylpyridine；3-bromo-2-methyl-6-propan-2-yloxypyridine
• CAS: 1239611-34-7
• 化学式: C₉H₁₂BrNO
• 分子量: 230.104
• InChiKey: GYOFZTOVTHSQLP-UHFFFAOYSA-N

物化性质

• 沸点：
  244.0±35.0 °C(Predicted)
• 密度：
  1.333±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  22.1
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3-溴-6-异丙氧基甲基吡啶 在 正丁基锂 、 三乙胺 作用下， 以 四氢呋喃 、 正己烷 、 1,2-二氯乙烷 为溶剂， 反应 6.75h， 生成 3-chloro-1-(cyanomethylamino)-6-[(6-isopropoxy-2-methyl-3-pyridyl)methyl]-7,8-dihydro-5H-2,6-naphthyridine-4-carbonitrile
  参考文献：
  名称：

  [EN] 5,6,7,8-TETRAHYDRO-2,6- AND 2,7-NAPHTHYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF DISEASES RESPONSIVE TO CITRATE TRANSPORTER MODULATION
  [FR] DÉRIVÉS DE 5,6,7,8-TÉTRAHYDRO-2,6- ET 2,7-NAPHTYRIDINE DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DE MALADIES SENSIBLES À LA MODULATION DU TRANSPORTEUR DE CITRATE

  摘要：

  The invention relates to a compound according to general formula (I), which acts as an inhibitor of a citrate transporter, e.g. a sodium-coupled citrate transporter such as INDY (SLC13A5); to a pharmaceutical composition containing one or more of the compound(s) of the invention; to a combination preparation containing at least one compound of the invention and at least one further active pharmaceutical ingredient; and to uses of said compound(s), including the use as a medicament as well as the use in the treatment and/or prevention of a condition associated with the activity of a citrate transporter such as metabolic diseases and age related diseases.

  公开号：

  WO2023285583A1
• 作为产物：
  描述：

  5-溴-6-甲基-2(1H)-吡啶酮 、 异丙醇 生成 3-溴-6-异丙氧基甲基吡啶
  参考文献：
  名称：

  Amines or amino alcohols as GLYT1 inhibitors

  摘要：

  本发明涉及使用式I化合物，其中取代基在说明书和权利要求中描述，用于治疗精神病、记忆和学习功能障碍、精神分裂症、痴呆症、注意力缺陷障碍或阿尔茨海默病。本发明还涉及一些式I化合物和含有它们的药物组合物。

  公开号：

  US08367838B2

文献信息

• [EN] DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES<br/>[FR] COMPOSÉS DE PYRAZOLE DI-SUBSTITUÉS POUR LE TRAITEMENT DE MALADIES
  申请人：FGH BIOTECH INC

  公开号：WO2018049080A1

  公开（公告）日：2018-03-15

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).

  本文提供了化合物、包含这些化合物的药物组合物，以及使用这些化合物和组合物治疗与SREBP途径异常激活相关的疾病、疾病或紊乱的方法，包括代谢紊乱如肥胖、癌症、心血管疾病和非酒精性脂肪肝病（NAFLD），其中该化合物符合式（I）。
• AMINES OR AMINO ALCOHOLS AS GLYT1 INHIBITORS
  申请人：Kolczewski Sabine

  公开号：US20100210592A1

  公开（公告）日：2010-08-19

  The invention relates to the use of compounds of formula I wherein the substituents are described in the description and claims for the treatment of psychoses, dysfunction in memory and learning, schizophrenia, dementia, attention deficit disorders or Alzheimer's disease. The invention also relates to some compounds of formula I and pharmaceutical compositions containing them.

  本发明涉及使用式I中的化合物，其中取代基在描述和权利要求中描述，用于治疗精神病、记忆和学习功能障碍、精神分裂症、痴呆症、注意力缺陷障碍或阿尔茨海默病。本发明还涉及一些式I的化合物和含有它们的药物组合物。
• Di-substituted pyrazole compounds for the treatment of diseases
  申请人：FGH BIOTECH, INC.

  公开号：US11339142B2

  公开（公告）日：2022-05-24

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).

  本文提供了化合物、包含该化合物的药物组合物，以及使用该化合物和组合物治疗与 SREBP 通路异常活化相关的病症、疾病或紊乱的方法，包括代谢紊乱，如肥胖、癌症、心血管疾病和非酒精性脂肪肝（NAFLD），其中化合物根据式 (I)。
• AMINE OR AMINO ALCOHOLS AS GLYT1 INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP2398558A1

  公开（公告）日：2011-12-28
• DI-SUBSTITUTED PYRAZOLE COMPOUNDS FOR THE TREATMENT OF DISEASES
  申请人：FGH BIOTECH, INC.

  公开号：US20190194167A1

  公开（公告）日：2019-06-27

  Provided herein are compounds, pharmaceutical compositions comprising the compounds, and methods of using the compounds and compositions in treating a condition, disease, or disorder associated with abnormal activation of the SREBP pathway, including metabolic disorders such as obesity, cancer, cardiovascular disease, and nonalcoholic fatty liver disease (NAFLD) wherein the compound is according to Formula (I).